Massachusetts Life Sciences Center

The funding is being provided through the Massachusetts Life Sciences Center, which oversees the state's $1 billion life sciences investment plan.

The money from the Massachusetts Life Sciences Center will go toward developing a test that does not require laboratory instrumentation.

NEW YORK (GenomeWeb) – The Massachusetts Life Sciences Center today said that Roche has joined the Center's Corporate Consortium Partners to support early stage life science firms in the state.

NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center has released the list of firms that will receive a total of $25 million in tax incentives tied to job creation this year, and that list includes several omics and molecular diagnostics firms.

NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center has provided $8 million in funding to support continued development of the Center for Personalized Cancer Therapy, a joint initiative between the University of Massachusetts Boston and the Dana-Farber/Harvard Cancer Center (DF/HCC

NEW YORK (GenomeWeb News) – Illumina this week declared conformity with the requirements of the IVD Directive and has applied the CE mark for the MiSeqDx Cystic Fibrosis System.

NEW YORK (GenomeWeb News) – The Forsyth Institute plans to use a $4.1 million grant from the Massachusetts Life Sciences Center (MLSC) to create a new center that will develop saliva-based molecular diagnostic tests for assessing disease risk.

NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center announced on Wednesday it has awarded Firefly BioWorks a $500,000 matching grant.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.